THURSDAY | FEBRUARY 6, 2020
Pain Medicine Case Reports :
A Change in Direction and a Name Change
Interventional Pain Management Reports is now Pain Medicine Case Reports . Over the last few months, IPM Reports has undergone significant changes under the guidance of a new editorial board. Consequently, IPM Reports , now called Pain Medicine Case Reports, is much more than just a name change. This change in title represents what will be a seismic shift in the content, layout, and accessibility to clinical information on case reports in pain medicine and interventional pain management.

Pain Physicians know there is no special journal dedicated to publishing pain medicine reports. It has become increasingly harder to publish case reports in existing journals. As you know, the first journal in interventional pain management, Pain Physician, has stopped publishing case reports and other journals publish them sporadically. Pain Medicine Case Reports will also publish case series and letters to the editor.

The exponential growth of peer reviewed publications in interventional pain management and pain medicine makes it challenging for a clinical specialist to stay up-to-date on the case reports. Case reports are crucial in advancing the knowledge. Most of the evolution and innovations develop from case reports in the ever changing health care environment, it is crucial to be able to publish case reports which serve as the basis for the future knowledge.

“We are pleased to be offering this more narrow focus for the interventional pain management and pain medicine communities,” Said Dr. Laxmaiah Manchikanti, Chairman of the Board and CEO of ASIPP. “With Dr. Abd-Elsayed at the helm, we see great things for the future of this journal and the research offerings we will be able to publish and share to help those dealing with chronic pain.”

The journal will be under the new leadership of Dr. Alaa Abd-Elsayed. Dr. Abd-Elsayed assumed the duties of Editor in Chief of Pain Medicine Case Reports Jan. 1, 2020.
Any manuscripts currently accepted for IPM Reports will be published in Pain Medicine Case Reports . Any authors who have manuscripts currently in revision or review will have the opportunity to be moved for consideration in the updated journal.

Pain Medicine Case Reports is an official publication of the American Society of Interventional Pain Physicians (ASIPP) and is a sister publication of Pain Physician. Pain Medicine Case Reports is an open access journal, available online with free full manuscripts.
ABIPP Recognizes Your Knowledge and Expertise

The American Board of Interventional Pain Physicians ( ABIPP ) has developed certification programs that recognize accepted levels of knowledge and expertise in the interventional pain management profession, with the goal of improved patient care. Hundreds of qualified physicians have made the commitment to become ABIPP certified.

ABIPP now offers the only competency certification program for regenerative medicine.
 
For complete information about the examination requirements and to obtain an application packet, visit
www.abipp.org or call 270-554-9412 x4217 or by email at summer@asipp.org .
JUNE 27
ABIPP Part I  
  • Combined CSM/CCPM Exam for ABIPP Path
  • Competency Exam in Controlled Substance Management
  • Competency Exam in Coding, Compliance, and Practice Management
 
JUNE 27-28
ABIPP Part II  
  • ABIPP Competency Exam
  • Regenerative Medicine Competency Exam
  • Endoscopic Lumbar Decompression Competency Exam
 
939 Ridge Lake Blvd.,
Memphis, Tennessee 38120
JUNE 2020 ABIPP EXAMS AND COMPETENCY EXAMS
June 27 - June 28, 2020 | Hilton Memphis
Bret Scher, MD
Board Certified Cardiologist and Lipidologist
Medical Director and Host, The Diet Doctor Podcast
ASIPP® Annual Meeting 2020
To Feature "The Diet Doctor"
Dr. Bret Scher is a board certified cardiologist and lipidologist practicing in San Diego. He’s The Diet Doctor Medical Director, writes medical blogs, reviews guides and news stories for medical accuracy and hosts The Diet Doctor Podcast . When he started his own preventative wellness center he was introduced to the whole low-carb world. Being a bit skeptical at first, he was soon convinced by the benefits of a low-carb diet.

Dr. Scher is also the author of the book Your best health ever and has a blog and website at lowcarbcardiologist.com

This will be the 22nd annual meeting for ASIPP ® and is being held in conjunction with the Texas Pain Society . The Annual Meeting will be tailored to physicians, mid-level providers, and staff. You can register in several ways. By phone contact Cindy at 270-554-9412. Online click here . In addition, the Exhibitor Prospectus is available to prospective sponsors and vendors. Click here to access the Exhibitor Prospectus.

Reserve your hotel room at discounted rates. The ASIPP ® meeting room block is now open for reservations. You may book online or by phone. Discounted rates include date of March 31-April 5 and will be available until March 17. Reserve by phone: 1-877-803-7534. Use the Group Discount Code: G-SIPP. Click here to reserve your room online.

If you have questions about the room block or the meeting, contact Karen Avery at kavery@asipp.org / 270-554-9412 x 4210
QUICK LINKS

ASIPP Annual Meeting
Offering Optional ASAM Course


ASAM TREATMENT OF OPIOID USE DISORDER - BUPRENORPHINE PRESCRIPTION WAIVER COURSE
Course Includes 4 hours of online material at the conclusion of the course to provide the required 8 hours needed to obtain the waiver to prescribe buprenorphine in office-based treatment of opioid use disorders.

A $200 registration fee is in addition to the meeting registration fee.
ASAM course registrants must be registered attendees for the ASIPP 2020 Annual Meeting in Dallas. Onsite registration will be available as space allows or you may register in advance on your meeting registration form.
This course will only be offered Friday, April 3 and is open to Physicians, Nurse Practitioners, Clinical Nurse Specialists, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorder.
Announcing a New ASIPP Partnership - Fedora Billing and Revenue Cycle Management Company 
After long discussions, in addition to our NorCal liability program for ASIPP members, now we are able to offer unique benefits for revenue cycle management with billing, etc.

Fedora ( https://www.ifedora.com ) is a company known to many of our board members and others. ASIPP has reached an agreement with Fedora to provide exclusive discounts on billing or revenue cycle management that will decrease practice costs and promote growth, or at least stop deterioration. It is not just a billing company; they streamline the billing and receivable process and constantly update payor regulations keeping your practice up to on date on a daily basis. 

You may view the ASIPP billing program website at the following link:   https://www.asippbilling.com/  

Some of the ASIPP Billing Program highlights are below:
Up to 50% savings for ASIPP members for their billing or revenue cycle management for their offices and surgery centers:
 
  • Expertise in interventional pain management billing for all types of services
  • 99% Clearing House Rate
  • 95% First-Time Claim Passage
  • 23.4 Average Days in A/R
  • Eligibility and Benefits Verification 
  • Pre-Certification/Prior Authorization
  • Denials and A/R Management 
Opioid Prescriptions Are On the Decline in the United States, According to CDC Report
A new report issued by the  Centers for Disease Control and Prevention (CDC)  observed a decline in opioid prescriptions across almost a dozen states.

Drug overdoses claimed the lives of more than 70,000 persons in the U.S. in 2017, according to the analysis; a third of these deaths were related to opioids. A historical trend has been observed between the  opioid epidemic  and an increase in  opioid  prescriptions.

“Various factors contributed to the increase in opioid prescribing, including changing attitudes toward the role of opioids in  chronic pain management , calls for more liberal use of opioids by professional pain management societies, and state regulations that have encouraged the use of opioids for chronic pain management,” the report explains .
READ MORE  | DOCWIRE |
State of the Union:
No 'Socialist Takeover' in Healthcare, Trump Declares
Gives "ironclad pledge" on pre-existing condition protections; Democrats scoff

WASHINGTON -- In his third State of the Union address on Tuesday, President Trump spoke of lowering drug prices, protecting Americans from the novel coronavirus, and safeguarding the Medicare trust fund, but one pledge stood out.
"To those watching at home tonight, I want you to know: We will never let socialism destroy American healthcare!" Trump said to hearty applause from Republican lawmakers and guests.

The evening was fraught from beginning to end with partisan tensions. Before the president's speech, Speaker Nancy Pelosi (D-Calif.) put forward her hand to shake the President's and was rebuffed.

Throughout most of the evening Democrats sat stonily, hands clasped on their laps, while Republicans clapped enthusiastically at Trump's remarks. Democrats stood and clapped mainly in support of some but not all visiting guests. And at the conclusion of President Trump's remarks, a teary Pelosi, still on the dais, ripped in half what looked like a transcript of the president's remarks.
READ MORE | MEDPAGE TODAY |
Opinion: Unlawful stem cell products continue to harm people as FDA deadline looms
More than two years after the Food and Drug Administration updated its  regulatory framework for regenerative medicine , hundreds of businesses continue to sell unapproved stem cell products and other drugs derived from human blood and tissue. 

The framework clarified how the agency would oversee the growing market for these products, and it encouraged the development of new therapies while also aiming to restrain the proliferation of unproven — and often dangerous — stem cell treatments.  
READ MORE | THE HILL |
FOLLOW ASIPP ON TWITTER @ASIPP
Opioid Prescribing Behaviors — Prescription Behavior Surveillance System, 11 States, 2010–2016
Abstract
Problem/Condition:  In 2017, a total of 70,237 persons in the United States died from a drug overdose, and 67.8% of these deaths involved an opioid. Historically, the opioid overdose epidemic in the United States has been closely associated with a parallel increase in opioid prescribing and with widespread misuse of these medications. National and state policy makers have introduced multiple measures to attempt to assess and control the opioid overdose epidemic since 2010, including improvements in surveillance systems.

Period Covered:  2010–2016

Description of System:  The Prescription Behavior Surveillance System (PBSS) was created in 2011. Its goal was to track rates of prescribing of controlled substances and possible misuse of such drugs using data from selected state prescription drug monitoring programs (PDMP). PBSS data measure prescribing behaviors for prescription opioids using multiple measures calculated from PDMP data including 1) opioid prescribing, 2) average daily opioid dosage, 3) proportion of patients with daily opioid dosages ≥90 morphine milligram equivalents, 4) overlapping opioid prescriptions, 5) overlapping opioid and benzodiazepine prescriptions, and 6) multiple-provider episodes. For this analysis, PBSS data were available for 2010–2016 from 11 states representing approximately 38.0% of the U.S. population. Average quarterly percent changes (AQPC) in the rates of opioid
prescribing and possible opioid misuse measures were calculated for each state.

Results and Interpretation:  Opioid prescribing rates declined in all 11 states during
2010–2016 (range: 14.9% to 33.0%). Daily dosage declined least (AQPC: -0.4%) in Idaho and Maine, and most (AQPC: -1.6%) in Florida. The percentage of patients with high daily dosage had AQPCs ranging from -0.4% in Idaho to -2.3% in Louisiana. Multiple-provider episode rates declined by at least 62% in the seven states with available data. Variations in trends across the 11 states might reflect differences in state policies and possible differential effects of similar policies.

Public Health Actions:  Use of PDMP data from individual states enables a more detailed examination of trends in opioid prescribing behaviors and indicators of possible misuse than is feasible with national commercially available prescription data. Comparison of opioid prescribing trends among states can be used to monitor the temporal association of national or state policy interventions and might help public health policymakers recognize changes in the use or possible misuse of controlled prescription drugs over time and allow for prompt intervention through amended or new opioid-related policies.
READ MORE | MMWR |
Essentials of Regenerative Medicine in Interventional
Pain Management
Essentials of Regenerative Medicine in Interventional Pain Management is a book to bring concise, collective, and comprehensive information to interventional pain physicians practicing regenerative medicine in managing chronic pain. Regenerative medicine is an integral part of interventional pain management within the definitions of interventional pain management and interventional techniques.

Each chapter contains an introduction of the subject, historical context,pathophysiology, applicability of regenerative medicine with its evidence base, indications, anatomy, technical aspects, complications, and precautions for each topic when available and applicable. This comprehensive book consists of 35 chapters, more than 350 figures, and 50 tables.
Essentials of Regenerative Medicine in Interventional Pain Management
Submit Your Abstract To The ASIPP ® 2020 Annual Meeting Abstract/Poster Presentation

The 2020 Annual Meeting Abstract Submission form is now available!

Abstracts Deadline February 17, 2020
ABSTRACT SUBMISSION / GUIDELINES
Pain Physician January/February
2020 Articles Available Online Now
The January/February issue of Pain Physician features two surveys: one on prescription drugs in the workplace, and another on patient-reported outcome demographics. The issue also features randomized trials on pulsed radiofrequency on thoracic dorsal root ganglion, and the effects of intraoperative, low-dose ketamine on postsurgical pain after breast cancer.
Analysis/Survey
Prescription Drugs and the US Workforce: Results from a National Safety Council Survey
Alaa Abd-Elsayed, MD, Mathew Fischer, MD, Jonathan Dimbert, MS, and Kenneth James Fiala,BS

Demographic Factors Associated with Patient-Reported Outcome Measures in Pain Management
Jihad Abdelgadir, MD, Edmund W Ong, PhD, Salma M Abdalla, MD, John C Hunting, MPH, Mohamed Mustafa Diab, MD, Michael M Haglund, MD, PhD, C Rory Goodwin, MD, PhD, and Padma Gulur, MD

Randomized Trials
Pulsed Radiofrequency on Thoracic Dorsal Root Ganglion versus Thoracic Paravertebral Nerve for Chronic Postmastectomy Pain, A Randomized Trial: 6-Month Results
Diab Fuad Hetta, MD, Sahar Abdel Baky Mohamed, MD, Kawser Hofny Mohamed, MD, Taha Abd Elrazek Mahmoud, MD, and Hanan Ahmed Eltyb, MD

Effects of Intraoperative Low-Dose Ketamine on Persistent Postsurgical Pain after Breast Cancer Surgery: A Prospective, Randomized, Controlled, Double-Blind Study
Christine Kang MD, Ah-Reum Cho MD, PhD, Kyung-Hoon Kim MD, PhD, Eun-A Lee MD, Hyeon-Jeong Lee MD, PhD , Jae-Young Kwon MD, PhD, Haekyu Kim MD, PhD, Eunsoo Kim MD, PhD, Ji-Seok Baik MD, PhD, and Choongrak Kim MD, PhD
Chronic pain: prescribe mental health support as well as drugs, say experts

People with chronic pain should be prescribed social interventions, such as mental health support instead of just opioid painkillers, experts have said.

About 28 million adults  in the UK live with pain that has lasted three months or more, according to recent research. But  tackling such pain is challenging , with few effective treatments on offer.

“For long-term pain there are no medical treatments that work really well – that is a harsh fact,” said Dr Cathy Stannard, clinical lead for guidelines on chronic pain from the National Institute for  Health  and Care Excellence.
READ MORE | THE GUARDIAN |
DEPARTMENT OF JUSTICE NEWS
Four Detroit-Area Physicians Found Guilty of Health Care Fraud Charges for Role in Over $150 Million Health Care Fraud Scheme

A federal jury found four Detroit-area physicians guilty today of health care fraud charges for their roles in a scheme to administer unnecessary back injections to patients in exchange for prescriptions of over 6.6 million doses of medically unnecessary opioids. Patients were required to get the injections in order to get the prescriptions, some of which were resold on the street by drug dealers, the evidence at trial showed.

After a four-week trial, Spilios Pappas, 62, of Lucas County, Ohio, Joseph Betro, 59, of Oakland County, Michigan, Tariq Omar, 62, of Oakland County, Michigan, and Mohammed Zahoor, 53, of Oakland County, Michigan, were each found guilty of one count of conspiracy to commit health care fraud and wire fraud, and one count of health care fraud. Sentencing has been scheduled for July 16 for Pappas, July 17 for Betro, July 24 for Zahoor and July 30 for Omar before Chief U.S. District Judge Denise Page Hood of the Eastern District of Michigan, who presided over the trial. Seventeen other defendants, including eight other doctors, previously pled guilty in connection with the investigation. 

“These physicians subjected patients to medically unnecessary injections to reap millions in fraudulent billings. Worse still, they incentivized those treatments by offering opioid prescriptions in sky-high dosages meant for the terminally ill,” said Assistant Attorney General Brian A. Benczkowski of the Justice Department’s Criminal Division. “Today’s verdict shows that the Department will root out physicians who let dollar signs rather than medical need drive their treatment of patients.”

READ MORE | DOJ |
Federal Court Orders North Carolina Pharmacy and
Pharmacist to Pay $600,000 and to Permanently Cease Dispensing Opioids or Other Controlled Substances

A federal court in eastern North Carolina entered a consent judgment and permanent injunction requiring a North Carolina pharmacy, Farmville Discount Drug Inc., and its owner and pharmacist-in-charge, Robert L. Crocker, to pay $600,000 in civil penalties and to permanently cease dispensing opioids or other controlled substances, the Department of Justice announced today. Under the court’s order, Crocker will also surrender his license to practice pharmacy and never seek its renewal, and Farmville Discount Drug will permanently surrender its registration with the U.S. Drug Enforcement Administration (DEA).

The consent order resolves a complaint filed by the United States alleging that Farmville Discount Drug and Crocker repeatedly filled prescriptions for opioids and other controlled substances in violation of the Controlled Substances Act. The United States alleged that, for years, the defendants ignored well-known “red flags” of drug diversion and drug-seeking behavior when filling prescriptions for controlled substances. These prescriptions often involved well-known, highly addictive, and highly abused painkillers such as oxycodone, hydrocodone, hydromorphone, and methadone, along with other “potentiator” drugs — drugs that heighten the euphoric effects of opioids, like diazepam ( i.e. , Valium), alprazolam ( i.e. , Xanax), and zolpidem ( i.e. , Ambien). 

READ MORE | DOJ |
Control Your Waiting Room TV

Customized waiting room TV exclusively for ASIPP ® members. Create your own ad-free television broadcasts using our videos, custom informational slides and your own YouTube videos. Even add local weather reports, news and live messages.
GET YOUR OWN LOBBY TV CHANNEL | CLICK HERE FOR ASIPP-TV |
State Society Meetings
Send in your state society meeting news to Holly Long , hlong@asipp.org
ASIPP | Pain Physician Journal | Phone | Fax | Email